Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml
Exp Clin Endocrinol Diabetes 2022; 130(07): 484-492
DOI: 10.1055/a-1708-3214
DOI: 10.1055/a-1708-3214
Article
Novel Insight into the Mechanism of Metabolic Surgery Causing the Diversity in Glycemic Status in Type 2 Diabetes
Mengxiao Zhou‡
1
Key Laboratory of Clinical Diagnostics, North University of Hebei,
Zhangjiakou, China
2
Department of Blood Transfusion, Forth Hospital of Shijiazhuang,
Shijiazhuang, China
,
Lijuan Wang‡
3
Department of Day Care Unit, Gansu Hospital of Traditional Chinese
Medicine, Lanzhou, China
,
Lujin Zhou
1
Key Laboratory of Clinical Diagnostics, North University of Hebei,
Zhangjiakou, China
,
Xiaotong Chang
1
Key Laboratory of Clinical Diagnostics, North University of Hebei,
Zhangjiakou, China
,
1
Key Laboratory of Clinical Diagnostics, North University of Hebei,
Zhangjiakou, China
› Author Affiliations
Abstract
Metabolic surgery results in diverse glycemic status in patients with type 2 diabetes (T2D), including hyperglycemia without remission, significant amelioration of hyperglycemia with partial remission, complete restoration of euglycemia, or with prolonged remission, hyperglycemia recurrence in relapses after remission, or post-bariatric hypoglycemia. Unfortunately, it is not known how metabolic surgery leads to this diverse consequence. Here, we discuss the diversity of glycemic status associated with metabolic surgery and the potential mechanisms of T2D remission. We also highlight the relationship between the change in low-grade inflammation and T2D remission after metabolic surgery. We hypothesize that the level of inflammatory and anti-inflammatory cytokines controls the efficacy of metabolic surgery in patients with T2D. This hypothesis may provide further insight into the mechanism of the beneficial effects of metabolic surgery patients with T2D.
Publication History
Received: 05 July 2021
Received: 05 July 2021
Accepted: 23 November 2021
Article published online:
03 January 2022
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Runkel N, Brydniak R. Surgical treatment of metabolic syndrome. Visc Med 2016; 32: 352-356
- 2 Carlsson LM, Peltonen M, Ahlin S. et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704
- 3 Affinati AH, Esfandiari NH, Oral EA. et al. Bariatric surgery in the treatment of type 2 diabetes. Curr Diab Rep 2019; 19: 156
- 4 Rubino F, Nathan DM, Eckel RH. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Obes Surg 2017; 27: 2-21
- 5 Halpern B, Mancini MC. Type 2 diabetes and metabolic surgery guidelines and recommendations should urgently be unified. Acta Diabetol 2020; 15: 1-6
- 6 Purnell JQ, Dewey EN, Laferrère B. et al. Diabetes remission status during seven-year follow-up of the longitudinal assessment of bariatric surgery study. J Clin Endocrinol Metab 2021; 106: 774-788
- 7 Stenberg E, Thorell A. Insulin resistance in bariatric surgery. Curr Opin Clin Nutr Metab Care 2020; 23: 255-261
- 8 Valentí V, Cienfuegos JA, Becerril Mañas S. et al. Mechanism of bariatric and metabolic surgery: Beyond surgeons, gastroenterologists and endocrinologists. Rev Esp Enferm Dig 2020; 112: 229-233
- 9 Russel SM, Valle V, Spagni G. et al. Physiologic mechanisms of type II diabetes mellitus remission following bariatric surgery: A meta-analysis and clinical implications. J Gastrointest Surg 2020; 24: 728-741
- 10 Tsilingiris D, Koliaki C, Kokkinos A. Remission of type 2 diabetes mellitus after bariatric surgery: Fact or fiction?. Int J Environ Res Public Health 2019; 16: 3171
- 11 Buse JB, Caprio S, Cefalu WT. et al. How do we define cure of diabetes?. Diabetes Care 2009; 32: 2133-2135
- 12 Pérez-Pevida B, Escalada J, Miras AD. et al. Mechanisms underlying type 2 diabetes remission after metabolic surgery. Front Endocrinol (Lausanne) 2019; 10: 641
- 13 Madsen LR, Baggesen LM, Richelsen B. et al. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: A Danish population-based matched cohort study. Diabetologia 2019; 62: 611-620
- 14 Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219-234
- 15 Koliaki C, Liatis S, le Roux CW. et al. The role of metabolic surgery to treat diabetes: Current challenges and perspectives. BMC Endocr Disord 2017; 17(1): 50
- 16 Janero DR. Synthetic agents in the context of metabolic/bariatric surgery: Expanding the scope and impact of diabetes drug discovery. Expert Opin Drug Discov 2014; 9: 221-228
- 17 Chikunguwo SM, Wolfe LG, Dodson P. et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 6: 254-259
- 18 Hirsch FF, Pareja JC, Geloneze SR. et al. Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes. Obes Surg 2012; 22: 910-917
- 19 Yamaguchi CM, Faintuch J, Hayashi SY. et al. Refractory and new-onset diabetes more than 5 years after gastric bypass for morbid obesity. Surg Endosc 2012; 26: 2843-2847
- 20 Courcoulas AP, King WC, Belle SH. et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) Study. JAMA Surg 2018; 153: 427-434
- 21 Buchwald H, Buchwald JN. Metabolic (Bariatric and Nonbariatric) Surgery for type 2 diabetes: A personal perspective Review. Diabetes Care 2019; 42: 331-340
- 22 Marsk R, Jonas E, Rasmussen F. et al. Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986-2006 in Sweden. Diabetologia. 2010; 53: 2307-2311
- 23 Sarwar H, Chapman WH, Pender JR. et al. Hypoglycemia after Roux-en-Y gastric bypass: The BOLD experience. Obes Surg 2014; 24: 1120-1124
- 24 Lee CJ, Clark JM, Schweitzer M. et al. Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy. Obesity (Silver Spring) 2015; 23: 1079-1084
- 25 Evers SS, Kim KS, Bozadjieva N. et al. Continuous glucose monitoring reveals glycemic variability and hypoglycemia after vertical sleeve gastrectomy in rats. Mol Metab 2020; 32: 148-159
- 26 Craig CM, Liu LF, Deacon CF. et al. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia 2017; 60: 531-540
- 27 Kefurt R, Langer FB, Schindler K. et al. Hypoglycemia after Roux-En-Y gastric bypass: Detection rates of continuous glucose monitoring (CGM) versus mixed meal test. Surg Obes Relat Dis 2015; 11: 564-569
- 28 Salehi M, Vella A, McLaughlin T. et al. Hypoglycemia after gastric bypass surgery: Current concepts and controversies. J Clin Endocrinol Metab 2018; 103: 2815-2826
- 29 Marques AR, Lobato CB, Pereira SS. et al. Insights from the impact of meal composition on glucose profile towards post-bariatric hypoglycemia management. Obes Surg 2020; 30: 249-255
- 30 Lobato CB, Pereira SS, Guimarães M. et al. Use of flash glucose monitoring for post-bariatric hypoglycaemia diagnosis and management. Sci Rep 2020; 10: 11061
- 31 Patti ME, Goldfine AB. The rollercoaster of post-bariatric hypoglycaemia. Lancet Diabetes Endocrinol 2016; 4: 94-96
- 32 Pareek M, Schauer PR, Kaplan LM. et al. Metabolic surgery: Weight loss, diabetes, and beyond. J Am Coll Cardiol 2018; 71: 670-687
- 33 Douros JD, Tong J, D’Alessio DA. The effects of bariatric surgery on islet function, insulin secretion, and glucose control. Endocr Rev 2019; 40: 1394-1423
- 34 Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2014; 2: 152-164
- 35 Nguyen KT, Korner J. The sum of many parts: Potential mechanisms for improvement in glucose homeostasis after bariatric surgery. Curr Diab Rep 2014; 14(5): 481
- 36 Goldfine AB, Patti ME. Diabetes: metabolic surgery for T2DM--cure, or remission and relapse?. Nat Rev Endocrinol 2014; 10: 8-9
- 37 Grenier-Larouche T, Carreau AM, Carpentier AC. Early metabolic improvement after bariatric surgery: The first steps toward remission of type 2 diabetes. Can J Diabetes 2017; 41: 418-425
- 38 Hutch CR, Sandoval D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology 2017; 158: 4139-4151
- 39 Jiménez A, Mari A, Casamitjana R. et al. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes 2014; 63: 3372-3377
- 40 Vidal J, de Hollanda A, Jiménez A. GLP-1 is not the key mediator of the health benefits of metabolic surgery. Surg Obes Relat Dis 2016; 12: 1225-1229
- 41 Liou AP, Paziuk M, Luevano JM. et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013; 5: 178ra41
- 42 Tremaroli V, Karlsson F, Werling M. et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 2015; 22: 228-238
- 43 Aron-Wisnewsky J, Prifti E, Belda E. et al. Major microbiota dysbiosis in severe obesity: Fate after bariatric surgery. Gut 2019; 68: 70-82
- 44 Frikke-Schmidt H, O’Rourke RW, Lumeng CN. et al. Does bariatric surgery improve adipose tissue function?. Obes Rev 2016; 17: 795-809
- 45 Honka H, Salehi M. Postprandial hypoglycemia after gastric bypass surgery: From pathogenesis to diagnosis and treatment. Curr Opin Clin Nutr Metab Care 2019; 22: 295-302
- 46 Sheehan A, Patti ME. Hypoglycemia after upper gastrointestinal surgery: Clinical approach to assessment, diagnosis, and treatment. Diabetes Metab Syndr Obes 2020; 13: 4469-4482
- 47 Goldfine AB, Mun EC, Devine E. et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92: 4678-4685
- 48 Salehi M, Gastaldelli A, D’Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 2014; 146: 669-680.e2
- 49 Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab 2012; 38: 183-191
- 50 Saltiel AR. New therapeutic approaches for the treatment of obesity. Sci Transl Med 2016; 8: 323rv2
- 51 Fändriks L. Roles of the gut in the metabolic syndrome: An overview. J Intern Med 2017; 281: 319-336
- 52 Kuryłowicz A, Koźniewski K. Anti-inflammatory strategies targeting metaflammation in type 2 diabetes. Molecules 2020; 25: 2224
- 53 Guilherme A, Virbasius JV, Puri V. et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377
- 54 Burhans MS, Hagman DK, Kuzma JN. et al. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol 2018; 9: 1-58
- 55 Cancello R, Henegar C, Viguerie N. et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54: 2277-2286
- 56 Aron-Wisnewsky J, Tordjman J, Poitou C. et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 2009; 94: 4619-4623
- 57 Viardot A, Lord RV, Samaras K. The effects of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes and prediabetes. J Clin Endocrinol Metab 2010; 95: 2845-2850
- 58 Zhang C, Zhang J, Liu Z. et al. More than an anti-diabetic bariatric surgery, metabolic surgery alleviates systemic and local inflammation in obesity. Obes Surg 2018; 28: 3658-3668
- 59 Cotillard A, Poitou C, Torcivia A. et al. Adipocyte size threshold matters: Link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab 2014; 99: E1466-E1470
- 60 Debédat J, Sokolovska N, Coupaye M. et al. Long-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: Prediction and clinical relevance. Diabetes Care 2018; 41: 2086-2095
- 61 Kratz M, Hagman DK, Kuzma JN. et al. Improvements in glycemic control after gastric bypass occur despite persistent adipose tissue inflammation. Obesity (Silver Spring) 2016; 24: 1438-1445
- 62 Hagman DK, Larson I, Kuzma JN. et al. The short-term and long-term effects of bariatric/metabolic surgery on subcutaneous adipose tissue inflammation in humans. Metabolism 2017; 70: 12-22
- 63 Labrecque J, Laforest S, Michaud A. et al. Impact of bariatric surgery on white adipose tissue inflammation. Can J Diabetes 2017; 41: 407-417
- 64 Ouchi N, Parker JL, Lugus JJ. et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97
- 65 Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36: 461-470
- 66 Herder C, Peltonen M, Svensson PA. et al. Adiponectin and bariatric surgery: Associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study. Diabetes Care 2014; 37: 1401-1409
- 67 Sams VG, Blackledge C, Wijayatunga N. et al. Effect of bariatric surgery on systemic and adipose tissue inflammation. Surg Endosc 2016; 30: 3499-3504
- 68 de Luis DA, Calvo SG, Pacheco D. et al. Adiponectin gene variant RS rs266729: Relation to lipid profile changes and circulating adiponectin after bariatric surgery. Surg Obes Relat Dis 2018; 14: 1402-1408
- 69 Malin SK, Bena J, Abood B. et al. Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery. Diabetes Obes Metab 2014; 16: 1230-1238
- 70 Unamuno X, Izaguirre M, Gómez-Ambrosi J. et al. Increase of the adiponectin/leptin ratio in patients with obesity and type 2 diabetes after Roux-en-Y gastric bypass. Nutrients 2019; 11: 2069
- 71 Ding S, Lund PK. Role of intestinal inflammation as an early event in obesity and insulin resistance. Curr Opin Clin Nutr Metab Care 2011; 14: 328-333
- 72 Gagnon J, Sauvé M, Zhao W. et al. Chronic exposure to TNF-α impairs secretion of glucagon-like peptide-1. Endocrinology 2015; 156: 3950-3960
- 73 El-Salhy M, Umezawa K. Effects of AP‑1 and NF‑κB inhibitors on colonic endocrine cells in rats with TNBS‑induced colitis. Mol Med Rep 2016; 14: 1515-1522
- 74 Winer DA, Luck H, Tsai S. et al. The intestinal immune system in obesity and insulin resistance. Cell Metab 2016; 23: 413-426
- 75 Tuomi K, Logomarsino JV. Bacterial lipopolysaccharide, lipopolysaccharide-binding protein, and other inflammatory markers in obesity and after bariatric surgery. Metab Syndr Relat Disord 2016; 14: 279-288
- 76 Sanmiguel C, Gupta A, Mayer EA. Gut microbiome and obesity: A plausible Explanation for Obesity. Curr Obes Rep 2015; 4: 250-261
- 77 Härma MA, Adeshara K, Istomin N. et al. Gastrointestinal manifestations after Roux-en-Y gastric bypass surgery in individuals with and without type 2 diabetes. Surg Obes Relat Dis 2021; 17: 585-594
- 78 Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism 2017; 68: 133-144
- 79 Subramaniam R, Aliakbarian H, Bhutta HY. et al. Sleeve gastrectomy and Roux-en-Y gastric bypass attenuate pro-inflammatory small intestinal cytokine signatures. Obes Surg 2019; 29: 3824-3832
- 80 Rodrigues RS, Almeida ÉC, Camilo SM. et al. Gastric and jejunal histopathological changes in patients undergoing bariatric surgery. Arq Bras Cir Dig 2016; 29: 35-38
- 81 Sala P, Torrinhas RSMM, Fonseca DC. et al. Intestinal expression of toll-like receptor gene changes early after gastric bypass surgery and association with type 2 diabetes remission. Nutrition 2020; 79-80: 110885
- 82 Seong J, Kang JY, Sun JS. et al. Hypothalamic inflammation and obesity: A mechanistic review. Arch Pharm Res 2019; 42: 383-392
- 83 Jais A, Brüning JC. Hypothalamic inflammation in obesity and metabolic disease. J Clin Invest 2017; 127: 24-32
- 84 Kalsbeek A, Bruinstroop E, Yi CX. et al. Hypothalamic control of energy metabolism via the autonomic nervous system. Ann N Y Acad Sci 2010; 1212: 114-129
- 85 Milanski M, Arruda AP, Coope A. et al. Inhibition of hypothalamic inflammation reverses diet-induced insulin resistance in the liver. Diabetes 2012; 61: 1455-1462
- 86 Thaler JP, Yi CX, Schur EA. et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012; 122: 153-162
- 87 Puig J, Blasco G, Daunis-I-Estadella J. et al. Hypothalamic damage is associated with inflammatory markers and worse cognitive performance in obese subjects. J Clin Endocrinol Metab 2015; 100: E276-E281
- 88 McGavigan AK, Henseler ZM, Garibay D. et al. Vertical sleeve gastrectomy reduces blood pressure and hypothalamic endoplasmic reticulum stress in mice. Dis Model Mech 2017; 10: 235-243
- 89 Herrick MK, Favela KM, Simerly RB. et al. Attenuation of diet-induced hypothalamic inflammation following bariatric surgery in female mice. Mol Med 2018; 24: 56
- 90 Valenzano A, Tartaglia N, Ambrosi A. et al. The metabolic rearrangements of bariatric surgery: Focus on orexin-A and the adiponectin system. J Clin Med 2020; 9: 3327
- 91 Browning KN, Fortna SR, Hajnal A. Roux-en-Y gastric bypass reverses the effects of diet-induced obesity to inhibit the responsiveness of central vagal motoneurones. J Physiol 2013; 591: 2357-2372
- 92 Tracey K. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-428
- 93 van de Sande-Lee S, Pereira FR, Cintra DE. et al. Partial reversibility of hypothalamic dysfunction and changes in brain activity after body mass reduction in obese subjects. Diabetes 2011; 60: 1699-1704
- 94 Hankir MK, Rullmann M, Seyfried F. et al. Roux-en-Y gastric bypass surgery progressively alters radiologic measures of hypothalamic inflammation in obese patients. JCI Insight 2019; 4: e131329
- 95 Holdstock C, Lind L, Engstrom BE. et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond) 2005; 29: 1275-1280
- 96 Hansen EN, Torquati A, Abumrad NN. Results of bariatric surgery. Annu Rev Nutr 2006; 26: 481-511
- 97 Mallipedhi A, Prior SL, Barry JD. et al. Changes in inflammatory markers after sleeve gastrectomy in patients with impaired glucose homeostasis and type 2 diabetes. Surg Obes Relat Dis 2014; 10: 1123-1128
- 98 Zhang C, Zhang J, Liu Z. et al. More than an anti-diabetic bariatric surgery, metabolic surgery alleviates systemic and local inflammation in obesity. Obes Surg 2018; 28: 3658-3668
- 99 Hepprich M, Wiedemann SJ, Schelker BL. et al. Postprandial hypoglycemia in patients after gastric bypass surgery is mediated by glucose-induced IL-1β. Cell Metab 2020; 31: 699-709.e5
- 100 Kopsombut G, Shoulson R, Milone L. et al. Partial small bowel resection with sleeve gastrectomy increases adiponectin levels and improves glucose homeostasis in obese rodents with type 2 diabetes. World J Surg 2012; 36: 1432-1438
- 101 Højlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan Med J 2014; 61: B4890
- 102 Kihira Y, Miyake M, Hirata M. et al. Deletion of hypoxia-inducible factor-1α in adipocytes enhances glucagon-like peptide-1 secretion and reduces adipose tissue inflammation. PLoS One 2014; 9: e93856
- 103 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
- 104 Iwase M, Komorita Y, Fujii H. et al. Incidence of severe hypoglycemia and its association with serum adiponectin in Japanese patients with type 1 and insulin-treated type 2 diabetes: The Fukuoka Diabetes Registry. J Diabetes Investig 2020; 11: 1258-1264
